根治性前列腺切除术与立体定向放疗治疗临床局限性前列腺癌:PACE-A随机试验结果
PACE-A是一项3期开放标签随机对照试验,将低至中危局限性前列腺癌男性按1:1随机分配至立体定向体部放疗(SBRT)或前列腺切除术,共123例(前列腺切除术60例、SBRT 63例),中位随访60.7个月。2年时前列腺切除术组每日使用吸水尿垫≥1个的比例为50%(16/32),SBRT组为6.5%(3/46),差异估计为43%(95%CI 25%–62%);前列腺切除术组肠道评分优于SBRT组,而性功能评分SBRT组优于前列腺切除术组。
要点
- 2年时前列腺切除术组16/32(50%)每日使用≥1个吸水尿垫,SBRT组3/46(6.5%),差异估计43%(95%CI 25%–62%)。
- 2年时肠道评分前列腺切除术组中位100(IQR 100–100)优于SBRT组87.5(IQR 79.2–100),估计均值差8.9(95%CI 4.2–13.7)。
- 性功能评分前列腺切除术组18(IQR 13.8–40.3)差于SBRT组62.5(IQR 32.0–87.5)。
核心结论
- SBRT与较少的患者报告尿失禁和性功能障碍相关,但肠道困扰略多于前列腺切除术。
- 这些随机数据应为局限性中危前列腺癌患者的治疗决策提供参考。
研究设计与样本
- PACE为3期开放标签随机对照试验,PACE-A将低至中危局限性前列腺癌男性按1:1随机分配至SBRT或前列腺切除术,不允许使用雄激素剥夺治疗(ADT)。
- 2012年8月至2022年2月共随机123例男性(前列腺切除术60例、SBRT 63例),中位随访60.7个月,中位年龄65.5岁,中位前列腺特异性抗原(PSA)7.9 ng/ml,92%为美国国家综合癌症网络(NCCN)中危疾病;50例接受前列腺切除术、60例接受SBRT。
主要发现
- 2年时前列腺切除术组16/32(50%)每日使用≥1个吸水尿垫,SBRT组3/46(6.5%)(p < 0.001;分别有15例和2例每日使用1个尿垫),差异估计为43%(95%CI 25%–62%)。
- 2年时肠道评分前列腺切除术组中位100(四分位距100–100)优于SBRT组87.5(四分位距79.2–100)(p < 0.001),估计均值差8.9(95%CI 4.2–13.7)。
- 性功能评分前列腺切除术组18(四分位距13.8–40.3)差于SBRT组62.5(四分位距32.0–87.5)。
关键数值与推荐
- 共同主要结局为2年时扩展前列腺指数综合量表(EPIC-26)每日所需吸水尿垫数量和肠道领域评分。
- 次要终点为临床医生报告的毒性、性功能及其他患者报告结局。
临床怎么用
- 原文结论指出这些随机数据应为局限性中危前列腺癌患者的治疗决策提供参考。
局限性
- 局限性为招募缓慢和2年患者报告结局应答率不完整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Randomised data on patient-reported outcomes (PROs) for stereotactic body radiotherapy (SBRT) and prostatectomy in localised prostate cancer are lacking. PACE-A compared patient-reported health-related quality of life after SBRT with that after prostatectomy. METHODS: PACE is a phase 3 open-label, randomised controlled trial. PACE-A randomised men with low- to intermediate-risk localised prostate cancer to SBRT or prostatectomy (1:1). Androgen deprivation therapy (ADT) was not permitted. The coprimary outcomes were the Expanded Prostate Index Composite (EPIC-26) number of absorbent urinary pads required daily and bowel domain score at 2 yr. The secondary endpoints were clinician-reported toxicity, sexual functioning, and other PROs. KEY FINDINGS AND LIMITATIONS: In total, 123 men were randomised (60 undergoing prostatectomy and 63 SBRT) from August 2012 to February 2022. The median follow-up time was 60.7 mo. The median age was 65.5 yr and the median prostate-specific antigen (PSA) value 7.9 ng/ml; 92% had National Comprehensive Cancer Network (NCCN) intermediate-risk disease. Fifty participants received prostatectomy and 60 received SBRT. At 2 yr, 16/32 (50%) prostatectomy and three of 46 (6.5%) SBRT participants used one or more urinary pads daily (p < 0.001; 15 and two, respectively, used one pad daily); the estimated difference was 43% (95% confidence interval [CI]: 25%, 62%). At 2 yr, bowel scores were better for prostatectomy (median [interquartile range] 100 [100-100]) than for SBRT (87.5 [79.2-100]; p < 0.001), with an estimated mean difference of 8.9 between these (95% CI: 4.2, 13.7); sexual scores were worse for prostatectomy (18 [13.8-40.3]) than for SBRT (62.5 [32.0-87.5]). The limitations were slow recruitment and incomplete 2-yr PRO response rates. CONCLUSIONS AND CLINICAL IMPLICATIONS: SBRT was associated with less patient-reported urinary incontinence and sexual dysfunction, and slightly more bowel bother than prostatectomy. These randomised data should inform treatment decision-making for patients with localised, intermediate-risk prostate cancer.
引用
- van As N, Yasar B, Griffin C, et al. Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial. Eur Urol. 2024. PMID: 39266383. doi:10.1016/j.eururo.2024.08.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。